Ariceum Therapeutics Appoints Chief Business Officer
BERLIN, July 7, 2022 /PRNewswire/ --Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targetedradiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer.
- BERLIN, July 7, 2022 /PRNewswire/ --Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targetedradiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer.
- Manfred Rdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "We are delighted to have attracted such a high calibreindividual for this important role.
- Serge Sagodira, new Chief Business Officer of Ariceum Therapeutics, added: "I am excited to be taking on this new role, working with a team of experienced industry professionals to advance products that I believe have the potential to transform the treatment of very challenging cancers and ultimately significantly improve patient outcomes.
- Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers.